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a b s t r a c t
Cultured primary peripheral blood mononuclear cells (PBMC) represent a potentially physiologic in vitro
model of HIV-1 infection, but assessment of antibody-mediated HIV-1 neutralization using PBMC has
been hindered by donor variability and lack of a sustainable individual PBMC source. To advance this
model for HIV vaccine evaluation, intra- and inter-assay variability were assessed using monoclonal and
polyclonal antibodies and PBMC targets from multiple HIV-seronegative donors. Inter-assay variability
was introduced by using different PBMC for virus propagation, and more substantially, for assay targets.
Neutralization titers varied by as much as 4 logs when using different individual donor PBMC as targets;
variability was antibody-speciﬁc, with the greatest variation observed using an individual polyclonal
plasma. Pooling of multiple PBMC donors signiﬁcantly reduced median inter-assay variation to the level
of intra-assay variation, suggesting a pathway forward for establishing a uniform, sustainable and
standardized approach to the assessment of antibody function using a PBMC model.
Published by Elsevier Inc.
Introduction
It is generally believed that elicitation of broadly cross-reactive
antibodies will be important for an efﬁcacious HIV-1 vaccine and
may be critical for inducing sterilizing immunity (McMichael,
2006). While the development of vaccine approaches to elicit
antibodies has evolved considerably during the past two decades,
so too have the assays to assess neutralizing antibodies (NAb)
elicited by new products and by natural HIV infection (Albert et al.,
1990; Darden et al., 2000; Holl et al., 2006; Mascola et al., 2005;
Mascola et al., 2002; Nara and Fischinger, 1988; Petropoulos et al.,
2000; Polonis et al., 2008; Robert-Guroff et al., 1986). Accurate and
precise quantitation of HIV-1 neutralization has remained a
challenge facing HIV vaccine researchers, and several organiza-
tions have promoted efforts to increase neutralization assay
standardization. These groups include the National Institutes of
Health Division of AIDS NIH/DAIDS (D'Souza et al., 1997), The
World Health Organization Neutralization Network WHO/NeutNet
(Fenyo et al., 2009; Heyndrickx et al., 2012) and the Collaboration
for AIDS Vaccine Development (CAVD) funded by the Bill and
Melinda Gates Foundation (Brown et al., 2012; Edmonds et al.,
2010). Different assay platforms have been applied for assessing
HIV neutralization; pseudovirus-based assays utilizing CCR5-
expressing cell lines were initially advanced as a standardized,
reproducible and portable methods for assessing vaccine-induced
NAb (Mascola et al., 2005). The use of peripheral blood mono-
nuclear cells (PBMC) for HIV-1 neutralization assays has long been
considered to be an important platform, which may incorporate a
degree of physiologic relevance (Fenyo et al., 2009; Heyndrickx
et al., 2012; Mann et al., 2009; Paul et al., 2010; Polonis et al.,
2009; Rusert et al., 2009). In this in vitro system, activated PBMC
(containing a mixture of cell types, including the CD4þ T lym-
phocytes presumed to be a target for HIV in vivo) are used for
propagation of HIV-1 isolates and as assay targets. However, this
platform has been plagued by variability, technical challenges and
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a lack of consistent PBMC donor sources. Variation in PBMC from
different donors has been shown to impact HIV-1 binding,
susceptibility and replication kinetics (Cloyd and Moore, 1990;
Spira and Ho, 1995; Wainberg et al., 1987; Williams and Cloyd,
1991). Only recently has the effect of donor variation been
appreciated with respect to neutralizing antibody titers (Brown
et al., 2012; Edmonds et al., 2010; Moody et al., 2010; Paul et al.,
2010). Several lines of evidence have highlighted divergent results
obtained when using speciﬁc neutralization assays (i.e. reporter
cell line-based pseudovirus assays versus PBMC assays) and using
particular antibodies (Binley et al., 2004; Brown et al., 2007;
Brown et al., 2008; Choudhry et al., 2006; Fenyo et al., 2009;
Heyndrickx et al., 2012; Ketas et al., 2007; Mann et al., 2009;
Moody et al., 2010; Rusert et al., 2009). It appears that certain
antibodies or inhibitors show greater potency in one assay system
than the other, with both assays failing to detect different subsets
of NAb. The relevance of the data generated in these different
in vitro systems is still under consideration, and it remains unclear
as to which functional assay(s) are predictive of in vivo outcomes.
Currently, the TZM-bl pseudovirus assay, which is highly repro-
ducible and readily established in international settings (Mascola
et al., 2005), has been a preferred assay for immunogenicity in
many vaccine trials (Bakari et al., 2011; Haynes et al., 2012). In
addition, a CCR5þ T cell line (A3/R5-7) has also recently been
applied for vaccine assessment (McLinden et al., in preparation;
Monteﬁori et al., 2012). Until the best functional assay correlates
are deﬁned, it will be important to assess antibody responses in
both the well-standardized cell line platforms, as well as in assays
employing primary cells. This will be facilitated through a better
understanding of the sources of variation in these assays, and by
devising methods to increase reproducibility.
In the initially developed PBMC assays, uncloned primary HIV-1
isolates were used in approaches employing the reduction of HIV-1
p24 gag protein production as an endpoint. New molecular tools
have recently been developed to facilitate the assessment of HIV
inhibition, including infectious molecular clones (IMC) that carry a
luciferase reporter gene and can be used with primary cell targets
such as PBMC (Chenine et al., 2013; Edmonds et al., 2010). These
reagents have made it possible to conduct a large number of assays
using multiple antibodies and PBMC targets with higher throughput.
The present study was initiated through the CAVD Comprehensive
Antibody-Vaccine Immune Monitoring Consortium (CA-VIMC) to
characterize the inﬂuence of individual donor PBMC on assay
variability, and to facilitate PBMC neutralization assay standardiza-
tion. In this study, we have employed both monoclonal and poly-
clonal antibodies along with well-characterized reporter IMC, to
assess the variation contributed by differences in donor PBMC, and
to devise methods to reduce this variation. Here we demonstrate
that, in addition to screening donors for particular genetic poly-
morphisms (Brown et al., 2012) and for HIV permissivity, pooling of
different donor PBMC is a means to mitigate inter-assay variability.
These studies will provide important guidance for the approaches
required for standardization of HIV inhibition assays using PBMC and
other relevant primary cell types.
Results
The experimental design models used to test the effect of
different PBMC targets or different PBMC virus propagation
sources in PBMC neutralization assays are shown in Fig. 1. Panel
A depicts the use of a virus stock (ie. Virus A) in neutralization
assays where different PBMC (Targets 1, 2 or 3) are used as assay
targets. Panel B illustrates the propagation of a particular virus
(Virus A) using multiple PBMC to produce this same virus from
different sources (donors 1, 2 or 3). This is followed by use of the
different stocks (ie. Virus A/1 or A/2 or A/3) in NAb assays using a
single PBMC donor or cell line (Target 1) to assess variability
introduced in the results due to virus stock variation. The data that
follow indicate both of these scenarios as sources of inter-assay
variation, deﬁned as the fold difference between ID50 or IC50
values generated in two assays for which only one variable, either
the source of PBMC used for assay targets or for viral propagation,
was altered.
We ﬁrst sought to determine the extent of the variability in the
PBMC neutralization assay when using IMC produced directly from
293T cells after transfection, or by passaging 293T-derived IMC
through one individual PBMC donor. Additionally, these two types
of stocks were tested using multiple individual PBMC targets. Fig. 2
demonstrates that use of different PBMC as targets for HIV-1
neutralization results in signiﬁcant variation in neutralization
titers. Twenty different donor PBMC were used as targets to assess
neutralization proﬁles for two Renilla luciferase expressing IMC,
SF162 (Fig. 2A) and BaL (Fig. 2B); both subtype B IMC were
produced from 293T cells (open circles) or passaged through
PBMC from a single donor (closed circles). 293T-derived IMC were
consistently more infectious than PBMC propagated IMC, however,
no correlation between neutralization sensitivity and target infec-
tivity was found (data not shown). The IC50 or ID50 values obtained
by two operators were accepted and averaged if the range
between operators was less than 5-fold, an arbitrarily deﬁned
Fig. 1. Experimental design for HIV inhibition and neutralization assays employing
PBMC from different donors. (A) The same virus stock (virus A) was tested using
speciﬁc antibodies and using 3 different individual PBMC as target cells. (B) A
speciﬁc virus (virus A) was passaged to produce different virus stocks derived from
donor 1 (virus A/1), donor 2 (virus A/2), and donor 3 (virus A/3) and then tested
against the three stocks using speciﬁc antibodies, but the same PBMC (Target 1) for
target cells.
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maximum acceptable intra-assay variability (Brown et al., 2008).
No signiﬁcant differences were observed in neutralization proﬁles
for the PBMC-derived versus 293T-derived IMC. However, altering
the PBMC used as targets induced inter-assay variability that was
neutralization reagent-speciﬁc, and occurred even when 293T-
derived virus was used. As can be seen in Fig. 2, the neutralization
titers observed for the same virus/antibody pair could vary by as
much as four logs and was most pronounced for an individual
HIVþ polyclonal plasma (Ind.). As might be expected, the least
variation was observed for sCD4-mediated inhibition.
A spectrum of sensitivity of detection was observed among the
20 PBMC targets tested when titers for each reagent were ranked
and scored based on quartiles (Supplementary information Fig. 1).
For example, when using BC177 as the assay target, 93% of the
neutralizing titers were in the top two quartiles (most potent
neutralizing titers), while using BC165 as assay targets, 93% of
neutralizing titers were in the bottom two quartiles (least potent
neutralizing titers); this difference was statistically signiﬁcant
(po0.0001). Titers were also determined for all reagents using
the two 293T-derived IMC in a TZMbl target cell neutralization
assay (Fig. 2, red squares). TZMbl titers fell within the data range
shown for different PBMC targets with the exceptions of sCD4-
mediated inhibition of both viruses and b12 mAb against the BaL
IMC, for which TZMbl IC50s showed greater potency. In addition,
the polyclonal Pool and individual (Ind.) plasma reagents showed
lower potency against the BaL IMC on TZM-bl target cells.
A similar level of variability was observed whether the 50% or
80% endpoints were used, as shown for the 293T-derived IMC in
Supplementary information Fig. 2. The variation was not signiﬁ-
cantly higher for the IC50s or ID50s (black dots), as compared with
the IC80s or ID80s (red dots). In addition, the neutralization proﬁles
for a given clone (BaL or SF162) did not differ when the PBMC-
derived or the 293T-derived stocks were used. In fact, signiﬁcant
correlations were observed when the titers for the PBMC-derived
and 293T-derived matched IMC were compared (Spearman corre-
lations po0.0001 for both BaL and SF162 IMC, data not shown).
This is not surprising, as the same env clone was assessed in both
approaches.
The inter-assay variation for each inhibitory reagent was also
assessed by combining all data points for every donor cell/reagent
pair performed for each 293T-derived virus and reagent tested. In
Fig. 3, these values are graphed as fold-differences for all possible
paired comparisons of the values obtained using different PBMC
targets, [e.g. donor PBMC BC174, BC167 and BC172 were used to
generate ID50 values of 355, 1314 and 6074, respectively for
HIVþB Pool plasma using SF162 IMC, the resulting paired fold-
differences were 3.7 (BC174 versus BC167), 4.6 (BC167 versus
BC172) and 17.1 (BC174 versus BC172)]. Intra-assay variation
(between operators using the same reagents) was independent
of the reagent used and averaged 2.3-fold (n¼770 assays, exclud-
ing concordant negative results, indicated in Fig. 3 as “Intra”). The
black bars indicate mean fold-differences and the red line indi-
cates the 5-fold cut-off for intra-assay variation. Inter-assay
variability was calculated for all accepted assays performed in
the study; values determined for each reagent (using each indivi-
dual PBMC donor for targets) were then compared for all possible
donor pairs. The greatest fold-differences (in IC50 or reciprocal
titer) between donor pairs (plotted as “Fold Differences” on the
Y-axis) were observed using the individual HIVþ plasma (a
maximum of 7850-fold difference in ID50s), and the least variation
was observed using sCD4 (11-fold maximum difference in IC50s).
The 2G12 mAb also showed 4100-fold differences for several
donor pairs, and showed a mean fold-difference 410 (Fig. 3).
The effect of using different PBMC donors to propagate HIV-1,
as modeled in Fig. 1B, is demonstrated in Fig. 4. Using different
US-1 subtype B virus stocks, the fold-differences between the
values for the same antibodies are shown. Neutralization assays
were performed either using a single donor for PBMC targets, or
using TZM-bl reporter cells as targets. Virus stocks derived from
propagating the US-1 subtype B primary isolate in ﬁve different
individual PBMC donors were used as innocula and tested against
the b12, 2G12, 2F5 and 4E10 mAbs in a p24 endpoint neutraliza-
tion assay (PBMC targets) or in the luciferase reporter-based TZM-
bl cell line. Inter-assay differences of up to 48-fold could be seen in
IC50s when exchanging the different US-1 virus stocks and using
the same PBMC as targets (Fig. 4), but the overall variability
induced by altering the virus stock was much lower than that
observed when using the same stock and varying the PBMC targets
(as shown in Fig. 3). To assess whether the variability induced by
changing virus source would also be observed using a cell line
target, we performed the same neutralization experiments using
Fig. 2. The range in neutralization titers observed using different PBMC as targets
can vary by more than three logs. The IC50s (4E10, 2F5, b12, 2G12 and sCD4) or
ID50s (Pool, Ind., HIVþB sera/plasma) obtained using 20 individual PBMC as
neutralization assay targets are shown for the 293T-derived (open circles) or
PBMC-derived (closed circles) LucR-IMC for SF162 (A) and for BaL (B). Titers were
also determined for all reagents using the same 293T-derived LucR-IMC and TZMbl
target cells with Fireﬂy luciferase endpoint readings (red squares).
Fig. 3. The magnitude of inter-assay differences varies depending upon the HIV-
inhibitory reagent. The fold-differences between the titers obtained using all
possible paired comparisons of PBMC target cells are shown for the 293T-derived
viruses, and grouped by reagent tested.
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the reporter cell line, TZM-bl. The viral PBMC propagation source
did not contribute to inter-assay variability when using the cell
line as targets, as shown in Fig. 4. The mean inter- and intra-assay
fold-differences were both approximately 1.5. The inter-assay fold-
differences induced by varying the virus stocks were signiﬁcantly
higher when a PBMC donor target was used, as compared to when
the cell line target was used (po0.0001 for 2F5, 4E10 and b12;
p¼0.0012 for 2G12) (Fig. 4).
Once we had quantiﬁed the degree of variation observed using
this collection of PBMC, a well-known panel of antibodies and two
well-characterized IMC, we then sought to explore methods that
might reduce this variability. To normalize the neutralization
proﬁles observed using individual targets, PBMC were pooled in
efforts to create larger collections of target cells that might be
more uniform over a series of experiments. We ﬁrst assessed the
effects of PBMC pooling on virus growth, and saw little or no
change in virus titers for the two IMC (BaL and SF162) produced in
either PBMC or 293T cells, and titered on each of three individual
donors versus the pool of all three. As shown in Supplementary
information Fig. 3, although the variation was somewhat increased
when PBMC propagated stocks were used, the titers obtained on
any individual donor (black symbols) versus the pool of the three
donors (red triangle) were all within 4-fold.
To assess the effects of pooling PBMC targets in neutralization
assays, a subset (fourteen) of the twenty original donors (used for
Fig. 2) were used either as individual PBMC targets, or in pools of
four donors; each pool of four varied in composition. In Fig. 5, the
IC80s against both BaL and SF162 IMC using 2G12 (A), 4E10 (B),
sCD4 (C), and the reciprocal 80% titers for the HIVþB individual
plasma (D), the HIVþB pooled sera (E), and an HIV negative
human serum pool (F) are displayed. IC80/ID80 values were
reported instead of IC50/ID50 to effectively compare values for
pools versus individual donors, as certain reagents showed greater
potency when using pooled PBMC targets. Each reagent value is
graphed for data obtained using the 14 different PBMC (Individual)
and using 9–15 different pools of four PBMC (Pool). Pooling the
PBMC targets appears to normalize neutralization values and
reduced the ranges (or maximum fold-differences) between titers
by nearly a log for the polyclonal reagents. For both polyclonal
reagents and sCD4, the mean values of the individual PBMC titers
were nearly identical to the mean values obtained when using
pooled donor targets (as indicated by the center black lines).
However, for HIVþB individual plasma and SF162 IMC, pooling
donor targets statistically reduced the range and increased the
median titer of measured ID80s (p¼0.008). In the case of 2G12 and
4E10, PBMC pooling resulted in a statistically greater level of
neutralization measured for BaL IMC (p¼0.002) (Fig. 5A). This was
a reproducible ﬁnding and the mechanism for this increase in
antibody activity when pooled PBMC are used is under investiga-
tion. A non-neutralizing value of 25 (Fig. 5A–C) or 40 (Fig. 5D–F)
was graphed for all titers o25 μg/ml or reciprocal titers o40
respectively, as 25 μg/ml and 1:40 were the highest concentration
or lowest dilution tested (see dashed red lines). No variability or
Fig. 4. Virus stock propagation using different PBMC donors induces variation in
IC50s when using PBMC, but not cell line targets. Virus stocks derived from
propagating the US-1 subtype B primary isolate in ﬁve different individual PBMC
donors were tested against the b12, 2G12, 2F5 and 4E10 mAbs in a p24 endpoint
neutralization assay (single PBMC targets) or in the luciferase reporter-based TZM-
bl assay. The fold differences between values obtained using all possible paired
comparisons of the ﬁve virus stocks tested were combined and shown as Inter-
assay variability. The Intra- assay variability is displayed in the fold-differences
obtained between operators using the same reagents.
Fig. 5. Pooling of donor PBMC reduces the variation in neutralization observed in the PBMC assay. The IC80s against both BaL and SF162 293T-derived IMC are shown for
2G12, 4E10, and sCD4 in panels A, B and C, respectively. The reciprocal 80% titers for the HIVþB Individual plasma (D), the HIVþB pool (E), and an HIV negative human
serum pool (NHS, F) are also displayed for both viruses. Each reagent value is graphed for data obtained using the 14 different PBMC (Individual) and using 9–15 different
pools of four PBMC (Pool).
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increased background was observed for the HIV-negative serum
control when using either individual or pooled PBMC (Fig. 5F).
We next asked whether or not pooling higher numbers of
donor PBMC could have an even greater impact on normalizing
neutralization titers. For these experiments, 10 of the 20 original
donors were tested as individual PBMC targets (1), or were used to
make 5 pools of 2, 4, 6 or 8 different donors of varying composi-
tion. As shown in Fig. 6, pooling of as few as two different PBMC
donors can mitigate the variation in neutralization titers against
the SF162 IMC in the PBMC assay, particularly when testing the
3 mAbs (2G12, b12, 2F5); signiﬁcant reductions are indicated by an
asterix (n). It also appears that pooling of increased numbers of
different PBMC results in a further decrease in the fold-differences
observed between values compared for donor pools, particularly
for the polyclonal antibodies. When the pools consisted of
8 donors, nearly all (except one value for the HIVþB Pooled Sera)
values plotted for fold-differences remained below the 5-fold level
(Fig. 6, far right), substantially reducing the individual donor
variation observed in the PBMC assay to nearly that observed
when using cell lines. When combing the data across reagents,
pools of 4, 6 or 8 PBMC showed signiﬁcantly reduced variation
compared with individual PBMC (1) (po0.0001); the pool of
2 PBMC was inﬂuenced by the higher variability observed with
the HIVþB Ind plasma.
Discussion
Most HIV vaccine researchers believe that a functional antibody
response will be a critical component of a successful vaccine. This
view is supported by the protection from infection observed in
passive transfer experiments using neutralizing mAbs in animal
models (Baba et al., 2000; Hessell et al., 2010; Mascola, 2002;
Mascola et al., 2000; Nishimura et al., 2003; Parren et al., 2001;
Shibata et al., 1999). Although the role of NAbs in HIV pathogenesis
and protection remains to be completely deﬁned, eliciting an
antibody response capable of neutralizing primary isolates of
multiple HIV subtypes continues to be a goal of laboratories that
are developing and testing vaccines. It is therefore thought that
in vitro neutralization or HIV inhibition studies will contribute to
the selection of HIV-1 envelopes for incorporation into candidate
vaccines. In the RV144 Phase III canary pox prime and protein
boost vaccine trial conducted in Thailand, speciﬁc binding anti-
bodies against envelope, including antibodies against the V2-loop
of gp120, were the only demonstrated correlate of protection
(Haynes et al., 2012), highlighting the potential importance of the
accurate and physiologic measurement of functional antibody
activities.
In the present study, we assessed the inﬂuence of the use of
different PBMC donor cells in HIV-1 inhibition assays. Varying the
PBMC source for viral propagation induced some inter-assay
variation when a primary isolate was utilized, and this variability
due to propagation source was eliminated when using the TZM-bl
cell line as a target. In a study of neutralization of pseudoviruses
and primary isolates comparing both TZM-bl cells and PBMC as
neutralization targets, Mann et al. (2009) reported that both the
virus producer cells and target cells inﬂuence the magnitude of
neutralization, with the target cell differences exerting a more
dominant effect. Our ﬁndings are in agreement with this report, as
we also observed that using different individual PBMC targets has
the most pronounced effect on assay variability. In another study
comparing neutralization activities of 11 reagents against 30
pseudotyped viruses and using PBMC versus TZM-bl cell targets,
Rusert et al. found that, depending on the type of inhibitor used,
neutralization potencies could be shifted to a variable extent,
depending on the targets employed. They also observed that CD4
binding site activities were the least affected by the target cell
environment (Rusert et al., 2009). The inter-assay variability
induced by altering the source of PBMC targets in our study was
also neutralization reagent-speciﬁc, with the greatest variability
measured (over 4 logs) when an individual polyclonal plasma
was tested and the lowest variability observed using soluble
CD4. These ﬁndings have important implications for evaluation
of vaccine sera, and should be taken into consideration when
standardizing vaccine immunogenicity assays.
Numerous studies have highlighted differences that can be
observed in neutralization results, depending on the assay chosen
and on assay-speciﬁc parameters (such as virus dose and source,
incubation times, target cells, cell densities, etc.), and depending
on the antibodies employed in the assay. Studies of anti-lipid
mAbs, such as phosphatidyl inositol phosphate (PIP) mAbs, have
shown that targeting lipids in close proximity to the viral or host
cell machinery involved in HIV-1 infection can result in neutrali-
zation of the virus. Some of these mAbs neutralized HIV-1 only in
assays where PBMC were used as target cells, and not in the TZM-
bl cell pseudovirus assay (Brown et al., 2007; Moody et al., 2010).
One explanation for the discrepancy observed between cell line
and PBMC assays was the ﬁnding that certain antibody samples
may contain endotoxin, which can in turn induce monocytes
present in the PBMC to produce beta-chemokines that will inhibit
HIV-1 infection, confounding data interpretation (Geonnotti et al.,
2010). In addition, certain antibodies appear to bind to target cell
plasma membrane constituents, which also can induce production
of beta-chemokines in the PBMC assay (Matyas et al., 2010; Moody
et al., 2010). The numbers of monocytes remaining in the PBMC
assay after cell stimulation would then contribute to variation in
data obtained using different PBMC sources, and different cell
stimulation protocols. In prior studies, we found that the CD14þ
monocytes were substantially decreased due to adherence after
a 3–4 day PHA-stimulation. Thus, in our targets, variation in
numbers of monocytes should have little impact on the data
(Brown et al., 2012). Furthermore, we found that CD8 T cell-
depletion inﬂuenced viral propagation in only about 50% of the
donors tested, thus, the expense and labor associated with
depleting CD8 cells did not appear to be beneﬁcial in our
standardization efforts. Additionally, our laboratory recently
reported the signiﬁcant effects that variation in the number of
natural killer (NK) cells in PBMC targets can have on the results of
PBMC neutralization assays. Especially when using polyclonal sera
and bulk PBMC where NK cells are present, the HIV inhibition
observed in a four-day assay appeared to extend beyond the
process of neutralization of viral entry, with potential ADCC or
Fig. 6. Pooling as few as two donor PBMC targets can reduce the variation in
neutralization titers against SF162 IMC; pooling of 8 donors reduced variation for
all ﬁve antibodies to intra-assay levels. Ten of the 20 original donors (see Fig. 2)
were tested as individual PBMC targets (1), or were used to make 5 different pools
of 2, 4, 6 or 8 different donors (pools were of varying composition). For each of the
5 neutralizing antibodies shown, the fold-differences in IC50s or ID50s comparing all
possible pairs of targets are shown. Statistically signiﬁcant reductions in variability
using pooled PBMC as compared to individual PBMC are marked indicated by an
asterix (*).
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other Fc-receptor mediated effects measured (Brown et al., 2012).
This has been observed using human vaccine sera from the HIVIS
vaccine trials using DNA prime and MVA boost. In the initial trial
assessed (HIVIS03), the vaccine sera were negative in the TZM-bl
assay (including Tier 1 viruses), but positive in the PBMC assay
(Bakari et al., 2011). In subsequent studies, the HIV inhibitory
activity was lost when the target cells were depleted of NK cells
(Joachim et al., 2012, 2013). These ﬁndings indicate that differing
numbers of NK cells in leukophoresis donors will also contribute
to variability between HIV inhibition assays using PBMC target
cells. In our study on the inﬂuence of NK cells in PBMC-based HIV
neutralization, the numbers of CD4þ and CD8þ T cells in the
PBMC donors did not signiﬁcantly inﬂuence neutralization, while
NK cell depletion did (Brown et al., 2012). Pooling of PBMC from
multiple different donors might normalize variables from pool to
pool, creating target cell environments that represent a composite
sampling of mixtures of multiple different types of primary
effector and target cells.
We now demonstrate that pooling of previously cryopreserved
PHA-stimulated PBMC targets from multiple donors can mitigate
some of the inter-assay variability observed in the PBMC neutraliza-
tion assay. In their studies, both Rusert and Mann utilized fresh, CD8-
depleted PBMC pooled from three donors and then stimulated with
PHA and/or anti-CD3 mAb (with low standard deviations observed)
(Mann et al., 2009; Rusert et al., 2009). These data highlight the
multiple differences in PBMC preparation protocols used amongst
different laboratories, and also indicate the potential utility of donor
cell pooling. In our study, donor PBMC pooling reduced the varia-
bility, with little change in the overall mean neutralization proﬁles
observed for most virus/antibody pairs. Studies performed in the
Hanson laboratory at the California Department of Public Health have
also demonstrated an averaging effect on neutralization titers for
anti-gp120 IgGs and IgAs, when pooled donor PBMC target cells were
compared with individual donors (Paul et al., 2010). Donor pooling
may also provide additional beneﬁts for HIV propagation. For
example, pools of 3–4 donors have been shown to be superior to
the composite individual donors for isolation and propagation of
acute primary HIV-1 from plasmas collected during Fiebig stage I
(Lai-Hipp et al., 2011). Thus, the use of pools of PBMC from multiple
donors may extend beyond the standard beneﬁt of having an
abundant and more sustainable source of cells for assessment of
large numbers of samples from clinical protocols. While we did not
preselect donors based on CD8 T cell or NK cell numbers for this
study, in future studies it will be interesting to address further
standardization of the assay and data normalization by preparing
pools of puriﬁed CD4 T cells or CD8-depleted and NK-cell depleted
donors to assess the inﬂuence of these parameters on assay variation.
The source of the virus stocks used may also contribute to
variations observed in neutralization platforms. The complexity of
env quasispecies in primary isolate stocks, as compared to a single
env used to make pseudoviruses or IMC, might generate differ-
ences between assays. In addition, variations in the viral envelope
lipid bilayer, as produced in lymphocytes versus transformed
epithelial cells, or as produced in cells from different PBMC donors,
can also play a role in the differences observed in HIV inhibition or
neutralization (as shown for the US-1 primary isolate, Fig. 4).
Primary virus stocks grown in PBMC incorporate multiple host
proteins into the virus envelope, to include ICAM-1 and HLA-DR,
which have been shown to aid in infectivity, and potentially, in
evasion of neutralizing antibodies (reviewed in (Cantin et al.,
2005; Kolegraff et al., 2006)). The 293T cells used to produce
pseudoviruses and IMCs lack ICAM-1 and HLA-DR, which can alter
neutralization sensitivity. A study of the neutralization proﬁles for
three viral strains produced as pseudoviruses or IMCs in 293T cells,
or as PBMC-derived stocks through a single passage of the IMCs in
PBMC, was previously performed. While the 293T derived-IMCs
were more neutralization sensitive compared with PBMC-
passaged IMCs, the neutralization proﬁles for different envelopes
appeared to be consistent (Louder et al., 2005), similar to ﬁndings
reported here.
The use of novel reporter IMCs as the virus source reduced
PBMC assay workload, but not the variation related to PBMC donor
differences. A major objective of the studies presented here was to
identify methods to control the variables associated with PBMC
donor differences to facilitate advancement of a platform for
vaccine evaluation wherein primary cells can be utilized, in hopes
of increasing the physiologic relevance of methods employed.
However, it has not been conclusively proven that any particular
neutralization assay is the best predictor of vaccine efﬁcacy or
clinical outcome. There are simply reports in the literature that
describe how data obtained in particular assay platforms relate to
what can be observed in vivo. For example, in a study of clinical
isolates obtained from subjects passively immunized with the
2G12 neutralizing mAb, the in vivo activity of 2G12 (the emergence
of 2G12 escape mutations) was the best corroborated by the data
obtained using a PBMC assay. In the TZM-bl pseudovirus system,
50% of the viruses failed to reﬂect the emergence of 2G12
resistance after passive immunization (Mann et al., 2009).
In another study using samples from HIV-infected patients, a
clade-speciﬁc neutralization pattern with more potent neutralization
of matched-clade viruses using pooled antibodies was demonstrated
using primary isolates and a PBMC neutralization assay. The matrix
assessing a single representative Env-pseudotyped virus from each
isolate and the same antibody pools demonstrated a completely
different pattern of cross-clade neutralization, with little association
between matched-clade reagents (Brown et al., 2008). The identiﬁca-
tion of cross-clade relationships using a system where activated
primary lymphocytes are used as both target cells and as producer
cells for virus stocks, seems somewhat intuitive and could be
interpreted as in vivo relevant when using polyclonal antibodies
from natural infection. On the other hand, in several studies,
pseudovirus assays have been predictive or reﬂective of in vivo
escape and viral evolution in natural infection (Liao et al., 2013;
Monteﬁori et al., 2003; Richman et al., 2003). Additionally, subtype-
speciﬁc neutralization patterns have also been observed in other
studies using the pseudovirus assay (Li et al., 2006; Moore et al.,
2011; Oballah et al., 2011; Seaman et al., 2010).
Although there are identiﬁable disparities between neutralization
proﬁles obtained using different assay platforms, it is unclear what
the relative contribution of any speciﬁc assay will be toward
elucidating the correlates of in vivo protection, and toward selecting
the best candidate vaccine(s). Progress in HIV vaccine development
may be accelerated if vaccine-induced and newly developed anti-
bodies are assessed both in the rapid and reproducible pseudovirus
platform, and in primary cell-based assays, until a validated correlate
of antibody-mediated protection has been identiﬁed. A greater
understanding of the impact of variation in human PBMC on the
outcomes of functional antibody assays, particularly as applied in
international settings where the cells will come from subjects with
very different genetic backgrounds, will facilitate the measurement
of incremental improvements in the antibody responses to HIV
envelope immunogens. The evaluation and advancement of novel
vaccine candidates will be facilitated by an approach that provides a
comprehensive assessment of virus–antibody–host cell interactions.
Materials and methods
PBMC collection and culture
PBMCwere collected by leukophoresis from healthy donors under
an IRB-approved protocol. PBMC were isolated by Ficoll–Hypaque
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density gradient centrifugation and cryopreserved. Three days prior
to the assay, PBMC were thawed, stimulated with 1 mg/ml phytohe-
magglutinin (PHA) (Sigma, St. Louis MO) and 20% IL-2 (Roche,
Indianapolis, IN) and were cultured as previously described (Ping
et al., 2013). PBMC included in this study were selected at random
and were not pre-screened for NK cells or any other population;
however, PBMC containing the CCR5-Δ32 mutation were excluded.
Although fresh cells may be optimal for HIV-1 replication, cryopre-
served cells were used for all studies described in this manuscript in
order to have a sustainable source of PBMC available for repeated use
and for preparation of numerous different pooled or individual donor
PBMC as assay target cells.
Viruses and antibodies
Primary isolates or infectious molecular clones (IMC) were
propagated using frozen PBMC from speciﬁc individual donors
demonstrated to yield viral stocks containing 410 ng/ml of p24
within four days post-infection, or were 293T cell-derived. The
SF162 and BaL IMC containing the Renilla luciferase gene (LucR-
IMC) (Edmonds et al., 2010) were used; neutralization proﬁles
were assessed using these stocks and different target cells. Cell
line targets were used to further assess the inﬂuence of virus
source, and reporter IMC tested assay design and endpoint varia-
tion. The US-1 viral isolate was propagated in peripheral blood
mononuclear cells (PBMC), as previously described (Brown et al.,
2005). The range in neutralization potency using pooled versus
individual constituent PBMC was assessed using sCD4 (Progenics
Pharmaceuticals, Tarrytown, NY), the monoclonal antibodies
(mAbs) 2G12, 2F5, 4E10, and IgG1 b12 (Polymun Scientiﬁc Immu-
nobiologhishe, NuBdorfer Lande 11, Austria) and an individual
plasma (HIVþB Ind.) or pooled polyclonal sera (HIVþB Pool) from
HIVþ subjects from the U.S. who were enrolled (with informed
consent) in two different IRB approved protocols.
IMC stock preparation and titration
IMC stocks were prepared by transfecting 5106 293T cells
with 8 μg of the IMC plasmid DNA using the FuGene transfection
reagent (Roche, Indianapolis, IN). Culture supernatants were
harvested at day 3 and stored at 80 1C. The 50% tissue culture
infectious dose (TCID50) was determined using TZM-bl cells by
generating eight serial 4-fold dilutions of virus in triplicate wells in
96-well culture plates in a total volume of 100 μl of growth
medium (DMEM). To each well was added 1104 TZM-bl cells
suspended in 100 μl of growth medium containing 60 μg/ml
DEAE-dextran. After a 48-hour incubation at 37 1C in a humidiﬁed
5% CO2-95% air environment, culture medium was removed from
each well and the adherent cells were washed with 100 μl of
phosphate buffered saline (PBS). PBS was removed from the wells
and 20 μl of lysis buffer (Promega Corp, Madison, WI) diluted 1:5,
was added to cells. Plates were then subjected to two freeze/thaw
cycles. Afterward, 100 μl of reconstituted Luciferase Assay Sub-
strate (Promega Corp., Madison, WI) was added to each well for
measurements of luminescence using a Victor 2 luminometer
(Perkin-Elmer Life Sciences, Shelton, CT). The wells producing
relative luminescence units (RLU) 42.5 background were
scored as positive (Li et al., 2005) and the TCID50 was calculated
by the Spearman–Karber method.
Cell line-based (TZM-bl cell) neutralization assay
Equal volumes of virus, prepared at a dilution that, in pre-
titrations, yielded 200,000 RLU at 48 h post-infection were incu-
bated in triplicate with test sample, in six serial 4-fold dilutions, in
96-well culture plates with ﬁnal volume of 50 μl/well at 37 1C for
1 h. A 50 μl aliquot containing 1104 TZM-bl cells and 60 μg/ml
DEAE-dextran was added to each well for a total volume of 100 μl.
Each plate included wells with cells and virus (virus control) or
cells alone (background control). After 48 h, cells were lysed,
luminescence was measured as above and the 50% inhibitory dose
(ID50) was deﬁned as the dilution that resulted in a 50% reduction
in RLU compared to virus control wells after subtraction of
background RLU.
PBMC neutralization assay
The PBMC neutralization assay endpoints were p24 production
or Renilla luciferase expression. For the p24 endpoint neutraliza-
tion assays, viral isolates were prepared at a dilution that, in pre-
titrations, yielded Z10 ng/ml p24 at 4–6 days post-infection.
Virus stocks were combined with an equal volume (25 μl) of
either the test reagent or IL-2 medium [RPMI 1640 (Quality
Biologics, Gaithersburg, MD) with 100 U/ml penicillin 100 mg/
ml-streptomycin (Quality Biologics, Gaithersburg, MD), 2 mM
L-glutamine (Quality Biologics, Gaithersburg, MD), and 15% fetal
calf serum (FCS) (Gemini Bioproducts, Woodland, CA), and con-
taining 20 U/ml recombinant interleukin-2 (IL-2) (Roche, Indiana-
polis, IN)]. Samples were prepared in triplicate and incubated for
30 min at 37 1C in 96-well deep-well plates. PHA-stimulated PBMC
were then added at 1.5105 cells per well. All PBMC were PHA-
stimulated individually for 3–4 days before pooling equal numbers
of cells from each donor. Plates were incubated overnight, then
washed twice with 400 μl of wash medium (same as IL-2 medium,
but with 2% FCS instead of 15% FCS and without IL-2), then washed
once with IL-2 medium, then resuspended in 200 μl of IL-2
medium and transferred to round-bottom 96-well plates. On days
4 and 6, 100 μl of culture ﬂuid was harvested and assayed for p24
(measured by p24 antigen capture; Beckman-Coulter, Miami, FL).
For the PBMC assays where LucR-IMC were used, the virus and
antibodies were incubated as above, except that a dilution of IMC
was employed that had yielded at least 10,000 RLU for Renilla
luciferase activity in pre-titrations. Mean titers are reported from
the quadratic projections of the IC50 from 2–5 assays for each virus
and neutralization reagent pair. For both methods, assays were
performed by at least two different technicians; IC50 or ID50 values
were accepted and averaged if the range was less than 5-fold,
deﬁning the intra-assay variability.
Statistical analysis
When comparing the data for inter- and intra-assay differences,
the non-parametric Wilcoxon matched-pairs signed rank test was
utilized to examine overall signiﬁcance, and to determine which
groups of data showed signiﬁcant differences from the intra-assay
variation observed. Data were analyzed with Prizm 4.0b (Graph-
Pad Software, Inc., San Diego, CA).
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